Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 1

Conditions

Thyroid Neoplasms 1Neoplasm Metastasis 1Differentiated Thyroid Carcinoma 1

Interventions

Specimen Handling 449Magnetic Resonance Spectroscopy 344pembrolizumab 296Biopsy 247Carboplatin 235Cisplatin 198Cyclophosphamide 190Paclitaxel 167Nivolumab 158Gemcitabine 154Bevacizumab 125Radiotherapy 122Dexamethasone 115fludarabine 102Pemetrexed 102Fluorouracil 96Doxorubicin 92venetoclax 91durvalumab 91Radiation 91Docetaxel 91atezolizumab 90Oxaliplatin 89Rituximab 88Leucovorin 82Capecitabine 78Prednisone 77Lenalidomide 71Etoposide 69X-Rays 67

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Iodine-124 × 30 days × Clear all
NCT03841617 2026-06-05

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
30 enrolled
Head & Neck

Neoplasm Metastasis, Thyroid Neoplasms

NCT01704586 2026-05-12

CLERAD-PROBE

University of Wuerzburg

Phase NA Active not recruiting
340 enrolled
EndocrineHead & Neck

Differentiated Thyroid Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡